Compare · INMD vs NRXS
INMD vs NRXS
Side-by-side comparison of InMode Ltd. (INMD) and Neuraxis Inc. (NRXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INMD and NRXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- INMD carries a market cap of $3.41B.
- Over the past year, INMD is up 1.0% and NRXS is up 237.3% - NRXS leads by 236.3 points.
- NRXS has been more active in the news (5 items in the past 4 weeks vs 1 for INMD).
- INMD has more recent analyst coverage (20 ratings vs 0 for NRXS).
- Company
- InMode Ltd.
- Neuraxis Inc.
- Price
- $14.40+0.14%
- $7.86+5.93%
- Market cap
- $3.41B
- -
- 1M return
- +4.80%
- +3.97%
- 1Y return
- +1.02%
- +237.34%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- AMEX
- IPO
- 2019
- 2023
- News (4w)
- 1
- 5
- Recent ratings
- 20
- 0
InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Latest INMD
- InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
- InMode to Present at the 25th Annual Needham Virtual Healthcare Conference
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by new insider Mizrahy Moshe
- SEC Form 3 filed by new insider Kreindel Michael
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 6-K filed by InMode Ltd.
Latest NRXS
- Neuraxis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- NeurAxis Expands Payer Coverage with Four New Medical Policies
- Neuraxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- SEC Form 424B5 filed by Neuraxis Inc.
- NeurAxis, Inc. Announces Preferred Stock Dividend
- SEC Form 4 filed by Henrichs Timothy Robert
- SEC Form 4 filed by Carrico Thomas Joeseph
- SEC Form 4 filed by Carrico Brian Allen
- NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
- SEC Form 10-K filed by Neuraxis Inc.